FOR46

Phase 1Biologic

FFortis Therapeutics, Inc.

FOR46 is one of 52 biologic programs targeting Prostate Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Prostate CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Novantrone

Pfizer

Preclinical

5 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 8

Prednisone/prednisolone

Roche

Preclinical

3 9

Ifex

BBaxter Healthcare Corporation

Preclinical

—10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Active, not recruiting

Prostate Cancer

NCT05011188

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Active, not recruiting·RRahul Aggarwal·Phase 1/2·NCT05011188·44 enrolled

A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Completed·FFortis Therapeutics, Inc.·Phase 1·NCT03575819·56 enrolled

Multiple Myeloma1 trial

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Completed·FFortis Therapeutics, Inc.·Phase 1·NCT03650491·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for FOR46. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FOR46 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FOR46. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fortis Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: FFortis Therapeutics, Inc.

FOR46

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Prostate Cancer2 trials

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News